Thalidomide-associated hyperglycemia and diabetes: Case report and review of literature [12]

Diabetes Care

Volumn 26, Issue 4, 2003, Pages 1322-1323

  Pathak, Ram D ^b   Jayaraj, Kandaswamy ^a   Blonde, Lawrence ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; GLIPIZIDE; GLUCOCORTICOID; INSULIN; STEROID; THALIDOMIDE;

AGED; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC DIET; DISEASE ASSOCIATION; DISEASE COURSE; DRUG FORMULATION; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; LETTER; MALE; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 0043169478     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.4.1322-a     Document Type: Letter

References (3)

1. Iqbal N, Zayed M, Boden G: Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes. Diabetes Care 23:1172-1176, 2000
2. Wilson JS, Vallance-Owen J: Congenital deformities and insulin antagonism. Lancet 2:940-941, 1966
3. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28 (4 Suppl. 15):62-66, 2001